Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy - Nature

What the report says

Nature.com reported on a study examining how aging-related inflammation may influence cancer progression and response to immunotherapy. The researchers found that older mice, and human samples referenced in the paper, had higher levels of pro-inflammatory myeloid immune cells producing cytokines including IL-1α, IL-1β, IL-6 and TNF-α. In mouse breast cancer models, these inflammatory myeloid cells were enriched in tumors and were linked with faster tumor growth and poorer survival.

The study used preclinical approaches including heterochronic parabiosis, in which young and aged mice share circulation, and bone marrow chimera experiments to investigate whether youthful circulating factors could reduce age-associated immune inflammation. The authors concluded that the suppressive factor was not derived from bone marrow cells and identified thymulin, a peptide produced by the thymus that decreases with age, as a candidate regulator.

According to the report, thymulin reduced inflammatory cytokine production by restraining NF-κB signaling in myeloid cells. In aged mice, thymulin also improved anti-tumor T-cell immunity, helped control tumor growth, extended survival and made tumors more responsive to anti-PD-L1 therapy, with effects described as age-dependent.

The findings point to a possible thymus–myeloid cell pathway connecting aging, chronic inflammation and cancer immunity. The work is preclinical, so it does not establish thymulin as an approved or proven treatment for older cancer patients. It does, however, add to broader evidence that age-related inflammation can limit checkpoint immunotherapy and may be a target for future therapeutic strategies.